Paper750106
The clinical evaluation of analogues. I. The overall problem.
Carter SK. Cancer Chemother Pharmacol, 1978. Cited by 13 papers, by iCite.
Cite this record
ConductScience Library. The clinical evaluation of analogues. I. The overall problem. Papers, record 750106. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/750106
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Drug Evaluation | Major topic |
| Neoplasms | Major topic |
| Humans | |
| Research Design |
Source PubMed
References6
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 766582 | Toxicity of antineoplastic agents in man, chromosomal aberrations antifertility effects, congenital malformations, and carcinogenic potential. | Adv Cancer Res | 1975 | https://conductscience.org/library/papers/766582 | PubMed |
| 2 | 804350 | Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. | Cancer Res | 1975 | https://conductscience.org/library/papers/804350 | PubMed |
| 3 | 328137 | Clinical trials in cancer chemotherapy. | Cancer | 1977 | https://conductscience.org/library/papers/328137 | PubMed |
| 4 | 373904 | Cancer chemotherapy as it approaches middle age. | Cancer Chemother Pharmacol | 1978 | https://conductscience.org/library/papers/373904 | PubMed |
| 5 | 794496 | Cancer treatment today and its impact on drug development, with special emphasis on the phase II clinical trial. | J Natl Cancer Inst | 1976 | https://conductscience.org/library/papers/794496 | PubMed |
| 6 | 4534592 | Integration of chemotherapy into combined modality treatment of solid tumors. 1. The overall strategy. | Cancer Treat Rev | 1974 | https://conductscience.org/library/papers/4534592 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 7002528 | Cancer chemotherapy: new developments and changing concepts. | Drugs | 1980 | https://conductscience.org/library/papers/7002528 | PubMed |
| 2311167 | Modification of methyliminodiacetato-trans-R,R-1,2-diamminocyclohexane platinum(II) pharmacology using a platinum-specific monoclonal antibody. | Cancer Chemother Pharmacol | 1990 | https://conductscience.org/library/papers/2311167 | PubMed |
| 393427 | m-AMSA and PALA: two new agents in cancer chemotherapy. | Cancer Chemother Pharmacol | 1979 | https://conductscience.org/library/papers/393427 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/750106
GET https://conductscience.org/api/papers/v1/750106/authors